T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication

Published:2021-01 Issue:1 Volume:29 Page:75-85
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Ng Yu-Yang,Tay Johan C.K.,Li Zhendong,Wang Junjian,Zhu Jiangqing,Wang Shu

Funder

Ministry of Health -Singapore

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference39 articles.

1. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond;Quintás-Cardama;Leuk. Lymphoma,2019

2. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas;Levin;Am. J. Hematol.,2019

3. CAR T cell therapy: inroads to response and resistance;Brown;Nat. Rev. Immunol.,2019

4. NKG2D CARs as cell therapy for cancer;Sentman;Cancer J.,2014

5. ‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors;Gilham;Immunotherapy,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review;Pathology - Research and Practice;2024-10

2. Asiaticoside modulates human NK cell functional fate by mediating metabolic flexibility in the tumor microenvironment;Phytomedicine;2024-10

3. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

4. Harmonizing efficacy and safety: the potentials of CAR-NK in effectively addressing severe toxicities of CAR-T therapy in mantle cell lymphoma;International Journal of Surgery;2024-05-27

5. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies;Biological Chemistry;2024-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3